Fig. 1

APOH levels are significantly decreased in patients with sepsis. a LC–MS/MS was employed to identify potential biomarkers for sepsis in a pilot cohort, and ELISAs were used to confirm the expression of APOH in a validation cohort. A murine model of CLP-induced sepsis was employed to evaluate the therapeutic impact of APOH. b LC‒MS/MS was employed to identify the level of APOH in patients with sepsis and healthy controls in the pilot cohort. c LC‒MS/MS was employed to identify the level of APOH in survivors and non-survivors with sepsis in the pilot cohort. d Serum levels of APOH in 36 paediatric patients with sepsis and 69 healthy controls in the validation cohort. e The dynamics of APOH levels in the serum of paediatric patients with sepsis at 24, 48 and 72 h in the validation cohort. The data are presented as the means ± standard deviations (S.D.). “*” indicates a difference between groups. *p < 0.05, **p < 0.01, *** p < 0.001, ****p < 0.0001. Apolipoprotein H, APOH; liquid chromatography tandem mass spectrometry, LC‒MS/MS; enzyme-linked immunosorbent assay, ELISA.